A review of neuroimaging biomarkers of Alzheimer's disease

Neurology Asia

Volumn 18, Issue 3, 2013, Pages 239-248

  Varghese, Tinu ^a,b   Sheelakumari, R ^a   James, Jija S ^c   Mathuranath, P S ^a,d  

^a Department of Neurology ^*  (India)

^b NOORUL ISLAM UNIVERSITY   (India)

^c SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^d NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

18F AV 45; AMYLOID BETA PROTEIN; FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B; TRACER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BOLD SIGNAL; BRAIN ATROPHY; BRAIN RADIOGRAPHY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAM; FLUORESCENCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MAGNETIC ENCEPHALOGRAPHY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RADIOLOGICAL PARAMETERS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOLUMETRY; VOXEL BASED MORPHOMETRY;

EID: 84885163326     PISSN: 18236138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment - a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand. 2002; 106:403-414.
2. Mathuranath PS, Cherian PJ, Mathew R, et al. Dementia in Kerala, South India: prevalence and infuence of age, education and gender. Int J Geriatr Psychiatry 2010; 25:290-297.
3. Zhang MY, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27:428-437.
4. de Silva HA, Gunatilake SB, Smith AD. Prevalence of dementia in a semi-urban population in Sri Lanka: report from a regional survey. Int J Geriatr Psychiatry 2003; 18:711-715.
5. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011; 29:26-32.
6. Wattamwar PR, Mathuranath PS. An overview of biomarkers in Alzheimer's disease. Ann Indian Acad Neurol 2010; 13:S116-S123.
7. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75(3):230-238.
8. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25:7709-7717.
9. Ortiz-Teran L, Santos JMR, Cabrera Martin MDL, Ortiz Alonso T. Currently available neuroimaging approaches in Alzheimers disease early diagonosis. In: De La Monte S, ed. The clinical spectrum of Alzheimer's disease - The charge toward comprehensive diagnostic and therapeutic strategies. New York: InTech, 2011: 147-180
10. Barber RC. Biomarkers for early detection of Alzheimers disease. J Am Osteopath Assoc 2010; 8:110-119.
11. Zhang L, Chang R, Chu L-W, Mak K-F. Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Am J Nucl Med Mol Imaging 2012; 2:386-404.
12. Ferreira LK, Busatto GF. Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics (Sao Paulo) 2011; 66 (Suppl 1):19-24.
13. Masdeua JC, Zubietab JL, Javier A. Neuroimaging as a marker of the onset and progression of AD. J Neurol Sci 2005; 236:55-64.
14. Karas GB, Scheltens P, Rombouts SA, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage 2004; 23:708-716.
15. Burns A, Zaudig M. Mild cognitive impairment in older people. Lancet 2002; 360:1963-1965.
16. Petersen RC. Mild cognitive impairment: Aging to Alzheimers disease. N Engl J Med 2003; 349:15-39.
17. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangelos E, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
18. McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimers disease: Quantitative structural neuroimaging for detection and prediction of clinical and structural changes in MCI. Radiology 2009; 251:195-205.
19. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010; 9:560-574.
20. Westman E, Simmons A, Zhang Y, et al. Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 2011; 54(2):1178-1187.
21. Wolz R, Julkunen V, Koikkalainen J, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One 2011; 6:e25446.
22. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461:916-922.
23. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol 2010; 31:347-354.
24. Desikan RS, Cabral HJ, Christopher P, et al. Automated MRI measures identify individuals with MCI and AD. Brain 2009; 132:2048-2057.
25. Devanand DP, Bensal R, Liu J, Hao X, Pradhaban G, Peterson BS. MRI hippocampal and entorhinal cortex mapping in predicting conversion to AD. Neuroimage 2012; 60:1622-1629.
26. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007; 68:828-836.
27. Duchesne S, Caroli A, Geroldi C, Barillot C, Frisoni GB, Collins DL. MRI-based automated computer classifcation of probable AD versus normal controls. IEEE Trans Med Imaging 2008; 27:509-520.
28. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27:685-691.
29. Frisoni GB, Fox NC, Clifford R. Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in AD. Nat Rev Neurol 2010; 6(2):67-77.
30. Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008; 39:1186-1197.
31. Colliot O, Chetelat G, Chupin M, et al. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology 2008; 248:194-201.
32. Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011; 76:1395-1402.
33. Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008; 70:191-199.
34. Smith AD, Jobst KA. Use of structural imaging to study the progression of AD. Br Med Bull 1996; 52:575-586.
35. Fennema-Notestine C, Hagler DJ Jr, McEvoy LK, et al. Structural MRI biomarker for Preclinical and mild Alzheimers disease. Hum Brain Mapp 2009; 30(10):3238-3253.
36. Robertsson B, Nordström M, Wijk H. Investigating poor insight in AD: A survey research approaches. Dementia 2007; 6:44-61.
37. Risacher SL, Shen L, West JD, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2009; 31:1401-1418.
38. Gerardin E, Chetelat G, Chupin M, et al. Multidimensional classifcation of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage 2009; 47:1476-1486.
39. Mechelli A, Price C J, Friston KJ, Ashburner J. Voxel-based morphometry of the human brain: Methods and applications. Current Medical Imaging Reviews 2005; 1:1-9.
40. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage 2000; 11:805-821.
41. Ishii K, Kawachi T, Sasaki H. et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. Am J Neuroradiol 2005; 26:333-340.
42. Masutani Y, Aoki S, Abe O, Hayashi N, Otomo K. MR diffusion tensor imaging: recent advance and new techniques for diffusion tensor visualization. Eur J Radiol 2003; 46:53-66.
43. Vasconcelos LG, Brucki SMD, Jackowiski AP, Bueno OFA. Diffusion tensor imaging for Alzheimers disease. Dement Neuropsychol 2009; 3:268-274.
44. Chua TC, Wen W, Slavin MJ, Sachdev PS. Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. Curr Opin Neurol 2008; 21:83-92.
45. Sundgren PC, Dong Q, Gomez-Hassan D, Mukherji SK, Maly P, Welsh R. Diffusion tensor imaging of the brain: review of clinical applications. Neuroradiology 2004; 46(5):339-350.
46. Alves GS, Sudo FK, Alves CEO, et al. Diffusion tensor imaging studies in vascular disease. A review of the literature. Dement Neuropsychol 2012; 6:158-163.
47. Clerx L, Visser PJ, Verhey F, Aalten P. New MRI markers for Alzheimer's disease: A meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimer Dis 2012; 29:1-9.
48. Medina D, DeToledo-Morrell L, Urresta F, et al. White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging 2006; 27(5):663-672.
49. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001; 13:534-546.
50. Wang K, Liang M, Wang L, et al. Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study. Hum Brain Mapp 2007; 28:967-978.
51. Tripoliti EE, Fotiadis DI, Argyropoulou M, Manis G. A six stage approach for the diagnosis of the Alzheimer's disease based on fMRI data. J Biomed Inform 2010; 43:307-320.
52. Wagner AD. Early detection of Alzheimer's disease: an fMRI marker for people at risk? Nat Neurosci 2000; 3:973-974.
53. Sperling R. Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann NY Acad Sci 2007; 1097:146-155.
54. Tripoliti EE, Fotiadis DI, Argyropoulou M. A supervised method to assist the diagnosis and classifcation of the status of Alzheimer's disease using data from an fMRI experiment. In: 30th Annual International Conference of the IEEE; 2008 20-24 August, 2008; Vancouver, Canada: IEEE, 2008: 4419-4422.
55. He Y, Wang L, Zang Y, et al. Regional coherence changes in the early stages of Alzheimer's disease: a combined structural and resting-state functional MRI study. Neuroimage 2007; 35:488-500.
56. Ellis KA, Rowe CC, Szoeke CE, et al. Advances in structural and molecular neuroimaging in Alzheimer's disease. Med J Aust 2011;194:S20-S23.
57. Bolmont T, Haiss F, Eicke D, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 2008; 28:4283-4292.
58. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008; 49:390-398.
59. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci 2000; 97:9226-9233.
60. Hefendehl JK, Milford D, Eicke D, et al. Repeatable target localization for long-term in vivo imaging of mice with 2-photon microscopy. J Neurosci Methods 2012; 205:357-363.
61. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319.
62. Jack CR, Lowe VJ, Senjem ML, et al. 11 C PiB and structural MRI provide complementary information in imaging of AD and MCI. Brain 2008; 131:665-680.
63. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefts. J Nucl Med 2002; 43:253-266.
64. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-forbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52:1210-1217.
65. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7:129-135.
66. Illan IA, Gorriz JM, Ramirez J, et al. Machine learning for very early Alzheimer's Disease diagnosis; a 18F-FDG and PiB PET comparison. In: Nuclear Science Symposium Conference Record (NSS/MIC), 2010 IEEE; 2010 Oct. 30 2010-Nov. 6 2010; Knoxville, Tennessee, USA: IEEE, 2010: 2334-2337.
67. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77(23):2034-2042.
68. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31:1275-1283.
69. Bourgeat P, Chetelat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74:121-127.
70. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000; 41:661-681.
71. Yanase D, Matsunari I, Yajima K, et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005; 32:794-805.
72. Xiong KL, Yang QW, Gong SG, Zhang WG. The role of positron emission tomography imaging of beta-amyloid in patients with Alzheimer's disease. Nucl Med Commun 2010; 31:4-11.
73. Mistur R, Mosconi L, De Santi S, et al. Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol 2009; 5:153-66.
74. Nobili F, Morbelli S. [18F]FDG-PET as a biomarker for early Alzheimer's disease. The Open Nuclear Medicine Journal 2010; 2:46-52.
75. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60:1374-1377.
76. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopic metabolite measurements in Alzheimer disease. Radiology 2008; 248:210-220.
77. Dixon RM BK, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in AD. Brain 2002; 125:2332-2341.
78. Stuhler E, Platsch G, Weih M, Kornhuber J, Kuwert T, Merhof D. Multiple discriminant analysis of SPECT data for alzheimer's disease, frontotemporal dementia and asymptomatic controls. In: Nuclear Science Symposium and Medical Imaging Conference (NSS/ MIC), 2011 IEEE; 2011 Oct. 27 2012-Nov. 3 2012; Anaheim, California, USA: IEEE, 2011: 4398-43401.
79. Matsuda H. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med 2007; 48:1289-1300.
80. Huang C, Eidelberg D, Habeck C, et al. Imaging markers of mild cognitive impairment: multivariate analysis of CBF SPECT. Neurobiol Aging 2007; 28:1062-1069.
81. Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002; 43:21-26.
82. Matsuda H, Mizumura S, Nagao T, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. Am J Neuroradiol 2007; 28:731-736.
83. Berendse HW, Verbunt JP, Scheltens P, van Dijk BW, Jonkman EJ. Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study. Clin Neurophysiol 2000; 111:604-612.
84. Zamrini E, Maestu F, Pekkonen E, et al. Magnetoencephalography as a putative biomarker for Alzheimer's disease. Int J Alzheimers Dis 2011 (2011), Article ID 280289.
85. Maestu F, Baykova E, Ruiz JM, et al. Increased biomagnetic activity in healthy elderly with subjective memory complaints. Clin Neurophysiol 2011; 122:499-505.
86. Fernandez A, Hornero R, Mayo A, Poza J, Gil-Gregorio P, Ortiz T. MEG spectral profile in Alzheimer's disease and mild cognitive impairment. Clin Neurophysiol 2006; 117:306-314.
87. Osipova D, Ahveninen J, Jensen O, Ylikoski A, Pekkonen E. Altered generation of spontaneous oscillations in Alzheimer's disease. Neuroimage 2005; 27:835-841.
88. Poza J, Hornero R, Abásolo D, Fernández A, García M. Extraction of spectral based measures from MEG background oscillations in Alzheimer's disease. Med Eng Phys 2007; 29:1073-1083.